Autifony Therapeutics
Trending Articles
Related Content
Research & Development
Autifony recieves Orphan Drug Designation to treat Fragile X
Autifony Therapeutics, developers of novel pharmaceutical treatments for serious disorders of the central nervous system, announced the US Food and Drug Administration has granted AUT00206 an Orphan Drug Designation for the treatment of Fragile X Syndrome